SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
The Role of Economic Evidence in Canadian Oncology Reimbursement Decision-Making: To Lambda and Beyond
15 references·3 citing·45 second hop
The Role of Economic Evidence in Canadian Oncology Reimbursement Decision-Making: To Lambda and Beyond (2008)The Role of Economic Evidence in Canadian…Priority setting at the micro-, meso- and macro-levels in Canada, Norway and Uganda (2006)Priority setting at the micro…Bringing ‘the public’ into health technology assessment and coverage policy decisions: From principles to practice (2006)Bringing ‘the public’ into he…Bias in published cost effectiveness studies: systematic review (2006)Bias in published cost effect…Quality, Innovation, and Value for Money (2005)Quality, Innovation, and Valu…Incremental cost-effectiveness ratios (ICERs): The silence of the lambda (2005)Incremental cost-effectivenes…Drug Prices and Value for Money (2005)Drug Prices and Value for Mon…Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge? (2004)Use of Cost-Effectiveness Ana…Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle (2004)Inclusion of cost effectivene…Fairness, accountability for reasonableness, and the views of priority setting decision-makers (2002)Fairness, accountability for …Priority-setting decisions for new cancer drugs: a qualitative case study (2001)Priority-setting decisions fo…Problems With the Interpretation of Pharmacoeconomic Analyses (2000)Problems With the Interpretat…Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. (1993)Guidelines for the adoption o…How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)How attractive does a new tec…The Discovery of Grounded Theory: Strategies for Qualitative Research. (1968)The Discovery of Grounded The…The Discovery of Grounded Theory: Strategies for Qualitative Research (1968)The Discovery of Grounded The…Cost-Utility Analysis of Cancer Prevention, Treatment, and Control (2015)Cost-Utility Analysis of Canc…Economic Evaluation of Frequent Home Nocturnal Hemodialysis Based on a Randomized Controlled Trial (2013)Economic Evaluation of Freque…Health Technology Assessment in Canada: 20 Years Strong? (2009)Health Technology Assessment …Foundations of Cost-Effectiveness Analysis for Health and Medical Practices (1977)Quality-adjusted Life Years, Utility Theory, and Healthy-years Equivalents (1989)QALYs and the equity-efficiency trade-off (1991)Assessing the costs of healthcare technologies in clinical trials. (1999)Cost effectiveness analysis in health care: contraindications (2002)Canʼt Get No Satisfaction? Will Pay for Performance Help? (2010)A methodological framework for assessing health indices (1985)Measurement of health state utilities for economic appraisal (1986)Meta-Analyses of Randomized Controlled Trials (1987)Costs, effects and C/E‐ratios alongside a clinical trial (1994)A study of the quality of life and cost-utility of renal transplantation (1996)Multiattribute Utility Function for a Comprehensive Health Status Classification System (1996)Cost-Effectiveness in Health and Medicine (1996)Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold (2008)What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? (2008)The Existence of Publication Bias and Risk Factors for Its Occurrence (1990)Conceptualizing a Model: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2 (2012)Estimating QALY Gains in Applied Studies: A Review of Cost-Utility Analyses Published in 2010 (2014)Corporate practices and health: a framework and mechanisms (2018)Cost-Effectiveness Analysis and the Consistency of Decision Making (2001)Health Economic Guidelines—Similarities, Differences and Some Implications (2001)Theory versuspractice: a review of ?willingness-to-pay? in health and health care (2001)Measuring Preferences for Cost-Utility Analysis (2007)Coverage with Evidence Development, Only in Research, Risk Sharing, or Patient Access Scheme? A Framework for Coverage Decisions (2012)Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC—Does the Presence of an Explicit Threshold Affect the ICER Proposed? (2018)The Concept of Representation (1967)The Concept of Representation, by Hanna F. Pitkin (1969)Participation and Democratic Theory (1970)Engaging the public in priority‐setting for health technology assessment: findings from a citizens’ jury (2008)Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA (2018)Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward (2019)Cost-Effectiveness and Cost-Benefit Analyses in the Medical Literature (1992)Guidelines for authors and peer reviewers of economic submissions to the BMJ (1996)Common Methodological Flaws in Economic Evaluations (2005)The Role of Value for Money in Public Insurance Coverage Decisions for Drugs in Australia: A Retrospective Analysis 1994-2004 (2008)Patient-based health technology assessment: A vision of the future (2007)Cost-Effectiveness Thresholds: the Past, the Present and the Future (2018)A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States (2020)Classrooms as Communities (1997)Disrupted Routines: Team Learning and New Technology Implementation in Hospitals (2001)Sample Size Policy for Qualitative Studies Using In-Depth Interviews (2012)How Many Interviews Are Enough? (2005)Theory Building From Cases: Opportunities And Challenges (2007)Seeking Qualitative Rigor in Inductive Research (2012)
this work references cited by second hop

References

  • 1968The Discovery of Grounded Theory: Strategies for Qualitative Research.46,361 cited
  • 1968The Discovery of Grounded Theory: Strategies for Qualitative Research6,679 cited
  • 1992How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.1,581 cited
  • 2004Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?790 cited
  • 2006Bias in published cost effectiveness studies: systematic review383 cited
  • 2005Incremental cost-effectiveness ratios (ICERs): The silence of the lambda253 cited
  • 2006Bringing ‘the public’ into health technology assessment and coverage policy decisions: From principles to practice245 cited
  • 2000Problems With the Interpretation of Pharmacoeconomic Analyses224 cited
  • 2004Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle194 cited
  • 1993Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem.173 cited
  • 2005Quality, Innovation, and Value for Money160 cited
  • 2006Priority setting at the micro-, meso- and macro-levels in Canada, Norway and Uganda145 cited
  • 2002Fairness, accountability for reasonableness, and the views of priority setting decision-makers139 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

  • 2005Drug Prices and Value for Money115 cited
  • 2001Priority-setting decisions for new cancer drugs: a qualitative case study111 cited
  • Cited by

    • 2009Health Technology Assessment in Canada: 20 Years Strong?70 cited
    • 2015Cost-Utility Analysis of Cancer Prevention, Treatment, and Control70 cited
    • 2013Economic Evaluation of Frequent Home Nocturnal Hemodialysis Based on a Randomized Controlled Trial69 cited